Neuropathy resembling CIDP in patients receiving tumor necrosis factor-α blockers
Authors:
- 26 April 2005
- journal article
- case report
- Published by Wolters Kluwer Health in Neurology
- Vol. 64 (8) , 1468-1470
Abstract
Tumor necrosis factor-alpha (TauNuFalpha) blockers are effective in the treatment of inflammatory arthritis but can induce autoimmune disorders including multiple sclerosis. Described are two patients who developed chronic inflammatory demyelinating polyneuropathy after initiation of anti-TNFalpha treatment.Keywords
This publication has 10 references indexed in Scilit:
- Etanercept (Enbrel®) therapy for chronic inflammatory demyelinating polyneuropathyJournal of the Neurological Sciences, 2003
- A new cause of hereditary small vessel diseaseNeurology, 2003
- Successful rechallenge with anti–tumor necrosis factor α for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: Comment on the article by Mohan et alArthritis & Rheumatism, 2002
- Recent advances in drug-induced neuropathiesCurrent Opinion in Neurology, 2002
- Demyelination occurring during anti-tumor necrosis factor ? therapy for inflammatory arthritidesArthritis & Rheumatism, 2001
- Approaches for identifying and defining environmentally associated rheumatic disordersArthritis & Rheumatism, 2000
- TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelinationNature Medicine, 1998
- Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2Neurology, 1996
- Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor‐immunoglobulin fusion proteinsEuropean Journal of Immunology, 1994
- Tumor necrosis factor identified in multiple sclerosis brain.Journal of Experimental Medicine, 1989